Top

Published in:

01-04-2018 | PRECLINICAL STUDIES

Antitumor activity of raloxifene-targeted poly(styrene maleic acid)-poly (amide-ether-ester-imide) co-polymeric nanomicelles loaded with docetaxel in breast cancer-bearing mice

Authors: Saeede Enteshari, Jaleh Varshosaz, Mohsen Minayian, Farshid Hassanzadeh

Published in: Investigational New Drugs | Issue 2/2018

Summary

Purpose Raloxifene (RA) receptors have over-expressed GPER-positive breast cancer tumors. The purpose of this work was to evaluate the antitumor activity and pharmacokinetic behavior of docetaxel (DTX), loaded in RA-targeted nanomicelles, which were designed to overcome a lack of specific distribution and inadequate DTX concentration in tumor tissues, as well as its cytotoxicity and damage to normal tissues. Methods DTX-loaded RA-targeted poly(styrene maleic acid) (SMA)- poly(amide-ether-esterimide)-poly(ethylene glycol) (PAEEI-PEG) nanomicelles were prepared; then, their antitumor activity and survival rate were studied in MC4-L2 tumors induced in BALB/c mice. The pharmacokinetics of DTX-loaded SMA-PAEEI-PEG-RA micelles was also investigated in comparison with free DTX. Results DTX-loaded SMA-PAEEI-PEG-RA micelles inhibited tumor growth considerably and increased animal survival as compared to free DTX and non-targeted micelles. SMA-PAEEIPEG-RA micelles enhanced significantly the area under the curve (AUC0-∞) 1.3 times as compared to free DTX and reduced clearance (CL) from 410.43 ml/kg.h (for free DTX) to 308.8 ml/kg.h (for SMA-PAEEI-PEG-RA micelles). Volume of distribution (Vdss) was also reduced 1.4 times as compared to free DTX. RA-targeted micelles increased tumor inhibition rate (TIR) 1.3 times and median survival time (MST) >1.5 times compared to free DTX. Percentage increase in life span (%ILS) was also enhanced significantly from 41.66% to >83.33% in MC4-L2 tumor-bearing BALB/c mice. Discussion All studies in this work showed the potential of DTX-loaded SMA-PAEEI-PEG-RA micelles in the treatment of GPER-positive receptor breast cancer tumors.

Jain V, Jain S, Mahajan S (2014) Nanomedicines based drug delivery systems for anti-cancer targeting and treatment. Curr Drug Deliv 12(2):177–191CrossRef

Liang X-J, Chen C, Zhao Y, Wang PC (2010) Circumventing Tumor Resistance to Chemotherapy by Nanotechnology. Methods Mol Biol 596:467–488CrossRefPubMedPubMedCentral

Byrne J, Betancourt T, Brannon-Peppas L (2008) Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 60(15):1615–1626CrossRefPubMed

Minko T, Rodriguez-Rodriguez L, Pozharov V (2013) Nanotechnology approaches for personalized treatment of multidrug resistant cancers. Adv Drug Deliv Rev 65(13):1880–1895CrossRefPubMed

Gemignani ML, Armstrong DK (2014) Breast cancer. Gynecol Oncol 132(2):264–267CrossRefPubMed

Liu B, Yang M, Li R, Ding Y, Qian X, Yu L, Jiang X (2008) The antitumor effect of novel docetaxel-loaded thermosensitive micelles. Eur J Pharm Biopharm 69(2):527–534CrossRefPubMed

Pazdur R, Cortes JE (1995) Docetaxel. J Clin Oncol 13(10):2643–2655CrossRefPubMed

Bharali DJ, Khalil M, Gurbuz M, Simone TM, Mousa SA (2009) Nanoparticles and cancer therapy: a concise review with emphasis on dendrimers. Int J Nanomedicine 4(1):1–7CrossRefPubMedPubMedCentral

Liu J, Zeng F, Allen C (2007) In vivo fate of unimers and micelles of a poly(ethylene glycol)-block-poly(caprolactone) copolymer in mice following intravenous administration. Eur J Pharm Biopharm 65(3):309–319CrossRefPubMed

10.

Qu G, Yao Z, Zhang C, Wu X, Ping Q (2009) PEG conjugated N-octyl-O-sulfate chitosan micelles for delivery of paclitaxel: in vitro characterization and in vivo evaluation. Eur J Pharm Sci 37(2):98–105CrossRefPubMed

11.

Alexis F, Pridgen E, Molnar LK, Farokhzad OC (2000) Factors affecting the clearance and biodistribution of polymeric nanoparticles. Biotechnology 18:412–420

12.

Manchun S, Dass CR, Sriamornsak P (2012) Targeted therapy for cancer using pH-responsive nanocarrier systems. Life Sci 90(11):381–387CrossRefPubMed

13.

Ganta S, Devalapally H, Shahiwala A, Amiji M (2008) A review of stimuli-responsive nanocarriers for drug and gene delivery. J Control Release 126(3):187–204CrossRefPubMed

14.

Yang C, Ebrahim Attia AB, Tan JPK, Ke X, Gao S, Hedrick JL, Yang Y-Y (2012) The role of non-covalent interactions in anticancer drug loading and kinetic stability of polymeric micelles. Biomaterials 33(10):2971–2979CrossRefPubMed

15.

Lappano R, Pisano A, Maggiolini M (2014) GPER function in breast cancer: an overview. Front Endocrinol 5:66CrossRef

16.

Cheng S-B, Graeber CT, Quinn JA, Filardo EJ (2011) Retrograde transport of the transmembrane estrogen receptor, G-protein-coupled-receptor-30 (GPR30/GPER) from the plasma membrane towards the nucleus. Steroids 76(9):892–896PubMed

17.

Thomas P, Pang Y, Filardo E, Dong J (2005) Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 146(2):624–632CrossRefPubMed

18.

Prossnitz ER, Sklar LA, Oprea TI, Arterburn JB (2008) GPR30: a novel therapeutic target in estrogen-related disease. Trends Pharmacol Sci 29(3):116–123CrossRefPubMed

19.

Carmeci C, Thompson DA, Ring HZ, Francke U, Weigel RJ (1997) Identification of a gene (GPR30) with homology to the G-protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer. Genomics 45(3):607–617CrossRefPubMed

20.

Hol T, Cox MB, Bryant HU, Draper MW (1997) Selective estrogen receptor modulators and postmenopausal women's health. J Women's Health 6(5):523–531CrossRef

21.

Sporn MB, Dowsett SA, Mershon J, Bryant HU (2004) Role of raloxifene in breast cancer prevention in postmenopausal women: Clinical evidence and potential mechanisms of action. Clin Ther 26(6):830–840CrossRefPubMed

22.

Varshosaz J, Enteshari S, Hassanzadeh F, Hashemi Bani B (2017) Synthesis of novel polystyrene-poly(amide-ether-ester-imide)-poly(ethylene glycol) co-polymeric micelles loaded with docetaxel: Physicochemical evaluation and cytotoxic effects on breast cancer cell lines. Mater Sci Mater Med (in press)

23.

Varshosaz J, Enteshari S, Hassanzadeh F, Hashemi Bani B (2017) Raloxifene targeted styrene maleic acid (SMA)-poly ether ester imide–poly ethylene glycol (PAEEI-PEG) copolymeric micelles for the targeted delivery of docetaxel: Physicochemical evaluation and cytotoxic effects on breast cancer cell lines. Polos One (in press)

24.

Lanari C, Lüthy I, Lamb CA, Fabris V, Pagano E, Helguero LA, Sanjuan N, Merani S, Molinolo AA (2001) Five novel hormone-responsive cell lines derived from murine mammary ductal carcinomas: in vivo and in vitro effects of estrogens and progestins. Cancer Res 61(1):293–302PubMed

25.

Taymouri S, Varshosaz J, Hassanzadeh F, Javanmard SH, Mahzouni P (2016) Pharmacokinetics, organ toxicity and antitumor activity of docetaxel loaded in folate targeted cholesterol based micelles. Curr Drug Deliv 13(4):545–556CrossRefPubMed

26.

Taheri A, Dinarvand R, Nouri FS, Khorramizadeh MR, Borougeni AT, Mansoori P, Atyabi F (2011) Use of biotin targeted methotrexate-human serum albumin conjugated nanoparticles to enhance methotrexate antitumor efficacy. Int J Nanomedicine 6:1863–1874PubMedPubMedCentral

27.

Zhao M, Su M, Lin X, Luo Y, He H, Cai C, Tang X (2010) Evaluation of docetaxel-loaded intravenous lipid emulsion: pharmacokinetics, tissue distribution, antitumor activity, safety and toxicity. Pharm Res 27(8):1687–1702CrossRefPubMed

28.

Ernsting MJ, Tang W-L, MacCallum NW, Li S-D (2012) Preclinical pharmacokinetic, biodistribution, and anti-cancer efficacy studies of a docetaxel-carboxymethylcellulose nanoparticle in mouse models. Biomaterials 33(5):1445–1454CrossRefPubMed

29.

Wang X, Li J, Wang Y, Cho KJ, Kim G, Gjyrezi A, Koenig L, Giannakakou P, Shin HJC, Tighiouart M (2009) HFT-T, a targeting nanoparticle, enhances specific delivery of paclitaxel to folate receptor-positive tumors. ACS Nano 3(10):3165–3174CrossRefPubMedPubMedCentral

30.

Deng C, Jiang Y, Cheng R, Meng F, Zhong Z (2012) Biodegradable polymeric micelles for targeted and controlled anticancer drug delivery: promises, progress and prospects. Nano Today 7(5):467–480CrossRef

31.

Zhao L, Y-m W, X-d Z, Liang Y, X-m Z, Li W, B-b L, Wang Y, Yu Y (2009) PK and tissue distribution of docetaxel in rabbits after i.v. administration of liposomal and injectable formulations. J Pharm Biomed Anal 49(4):989–996CrossRefPubMed

32.

Fang J, Nakamura H, Maeda H (2011) The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 63(3):136–151CrossRefPubMed

33.

Rezazadeh M, Emami J, Hasanzadeh F, Sadeghi H, Minaiyan M, Mostafavi A, Rostami M, Lavasanifar A (2016) In vivo pharmacokinetics, biodistribution and anti-tumor effect of paclitaxel-loaded targeted chitosan-based polymeric micelle. Drug Deliv 23(5):1707–1717

34.

Hu F-Q, Meng P, Dai Y-Q, Du Y-Z, You J, Wei X-H, Yuan H (2008) PEGylated chitosan-based polymer micelle as an intracellular delivery carrier for anti-tumor targeting therapy. Eur J Pharm Biopharm 70(3):749–757CrossRefPubMed

35.

Sausville EA, Burger AM (2006) Contributions of human tumor xenografts to anticancer drug development. Cancer Res 66(7):3351–3354CrossRefPubMed

36.

Song Y, Tian Q, Huang Z, Fan D, She Z, Liu X, Cheng X, Yu B, Deng Y (2014) Self-assembled micelles of novel amphiphilic copolymer cholesterol-coupled F68 containing cabazitaxel as a drug delivery system. Int J Nanomedicine 9:2307PubMedPubMedCentral

37.

Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, Richie JP, Langer R (2006) Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A 103(16):6315–6320CrossRefPubMedPubMedCentral

Title: Antitumor activity of raloxifene-targeted poly(styrene maleic acid)-poly (amide-ether-ester-imide) co-polymeric nanomicelles loaded with docetaxel in breast cancer-bearing mice
Authors: Saeede Enteshari
Jaleh Varshosaz
Mohsen Minayian
Farshid Hassanzadeh
Publication date: 01-04-2018
Publisher: Springer US
Published in: Investigational New Drugs / Issue 2/2018
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-017-0533-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 2/2018

Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer

Posterior reversible encephalopathy syndrome (PRES) induced by pazopanib, a multi-targeting tyrosine kinase inhibitor, in a patient with soft-tissue sarcoma: case report and review of the literature

A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer

Gastrointestinal perforation related to lenvatinib, an anti-angiogenic inhibitor that targets multiple receptor tyrosine kinases, in a patient with metastatic thyroid cancer

Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies

Association of Glutathione S-Transferase P-1 (GSTP-1) rs1695 polymorphism with overall survival in glioblastoma patients treated with combined radio-chemotherapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer